Dr. Steve Williamson, MD
Claim this profileThe University of Kansas Cancer Center (KUCC)
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Steve Williamson, MD is currently running
Ex Vivo Tumoroids
for Non-Small Cell Lung Cancer
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Recruiting1 award N/A10 criteria
Ipatasertib + Docetaxel
for Non-Small Cell Lung Cancer
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also known as AKT) in cancer patients. Importantly, evidence from preclinical studies has demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase (PI3'K)-AKT activity.
Recruiting1 award Phase 210 criteria
More about Steve Williamson, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Steve Williamson, MD has experience with
- Ascorbic Acid
- Melphalan
- Mitomycin C
- Ipatasertib
- Carboplatin
- Docetaxel
Breakdown of trials Steve Williamson, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Colorectal Cancer
Gastric Carcinomatosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steve Williamson, MD specialize in?
Steve Williamson, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Steve Williamson, MD currently recruiting for clinical trials?
Yes, Steve Williamson, MD is currently recruiting for 2 clinical trials in Fairway Kansas. If you're interested in participating, you should apply.
Are there any treatments that Steve Williamson, MD has studied deeply?
Yes, Steve Williamson, MD has studied treatments such as Ascorbic Acid, Melphalan, Mitomycin C.
What is the best way to schedule an appointment with Steve Williamson, MD?
Apply for one of the trials that Steve Williamson, MD is conducting.
What is the office address of Steve Williamson, MD?
The office of Steve Williamson, MD is located at: The University of Kansas Cancer Center (KUCC), Fairway, Kansas 66205 United States. This is the address for their practice at the The University of Kansas Cancer Center (KUCC).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.